Stoke Therapeutics (NASDAQ:STOK) General Counsel Jonathan Allan Sells 4,267 Shares

Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Jonathan Allan sold 4,267 shares of the business’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $33.01, for a total transaction of $140,853.67. Following the transaction, the general counsel directly owned 33,464 shares of the company’s stock, valued at approximately $1,104,646.64. This trade represents a 11.31% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Jonathan Allan also recently made the following trade(s):

• On Wednesday, March 18th, Jonathan Allan sold 4,628 shares of Stoke Therapeutics stock. The stock was sold at an average price of $31.34, for a total value of $145,041.52.

Stoke Therapeutics Trading Up 2.2%

Shares of NASDAQ STOK opened at $33.91 on Friday. Stoke Therapeutics, Inc. has a twelve month low of $5.35 and a twelve month high of $40.22. The company has a market capitalization of $2.01 billion, a price-to-earnings ratio of 50.61 and a beta of 1.07. The firm has a 50-day moving average of $32.60 and a two-hundred day moving average of $29.93.

Institutional Investors Weigh In On Stoke Therapeutics

A number of large investors have recently bought and sold shares of the company. Kestra Advisory Services LLC acquired a new position in shares of Stoke Therapeutics in the 4th quarter valued at approximately $26,000. Harbour Investments Inc. raised its holdings in Stoke Therapeutics by 312.9% during the 4th quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock worth $38,000 after purchasing an additional 898 shares during the last quarter. Generali Investments Management Co LLC acquired a new position in shares of Stoke Therapeutics in the 3rd quarter worth approximately $41,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Stoke Therapeutics by 31.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,776 shares of the company’s stock valued at $88,000 after purchasing an additional 658 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its position in shares of Stoke Therapeutics by 66.2% during the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after buying an additional 1,668 shares during the period.

More Stoke Therapeutics News

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Several firms reaffirmed or raised bullish views and price targets on STOK, supporting buying interest — Chardan reiterated a “Buy” rating. Chardan Capital Reiterates “Buy” Rating for Stoke Therapeutics (NASDAQ:STOK)
• Positive Sentiment: BTIG reaffirmed a Buy rating and set a $39 price target, signaling notable upside vs. recent levels and likely attracting momentum buyers. BTIG Research reaffirmation (Benzinga)
• Positive Sentiment: Wedbush raised its price target to $38 and Needham published a bullish outlook for strong price appreciation—additional analyst support that can underpin the rally. Wedbush Boosts Stoke Therapeutics (NASDAQ:STOK) Price Target to $38.00
• Positive Sentiment: Coverage of Stoke’s experimental program highlights broader clinical potential beyond seizure control — reporting suggests the drug aims to reverse developmental loss in Dravet syndrome, which supports longer‑term value. Beyond seizures: With experimental drug, Stoke aims to restore developmental loss in Dravet syndrome
• Neutral Sentiment: Analysis pieces examined a recent sharp pullback and the drivers behind it — useful context for traders but not new company-specific catalyst. Stoke Therapeutics (NASDAQ:STOK) What Triggered This Sudden Drop?
• Negative Sentiment: Multiple insiders (including the CFO, general counsel and other executives) disclosed sizable sales across March 17–19, trimming positions by double-digit percentages — insider selling can weigh on sentiment and prompt investor caution. Representative filing: SEC Form 4 (Jonathan Allan)

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. BTIG Research reaffirmed a “buy” rating and issued a $39.00 price target on shares of Stoke Therapeutics in a research report on Thursday. Loop Capital set a $35.00 price target on shares of Stoke Therapeutics in a report on Monday, January 5th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Stoke Therapeutics in a report on Monday, December 29th. Needham & Company LLC lifted their price objective on Stoke Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, Chardan Capital reissued a “buy” rating and issued a $35.00 target price on shares of Stoke Therapeutics in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, Stoke Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $39.83.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.